Characterization of immunophenotypes in glioblastoma (GBM) is important for therapeutic stratification and helps predict treatment response and prognosis. Radiomics can be used to predict molecular subtypes and gene expression levels. However, whether radiomics aids immunophenotyping prediction is still unknown. In this study, to classify immunophenotypes in patients with GBM, we developed machine learning-based magnetic resonance (MR) radiomic models to evaluate the enrichment levels of four immune subsets: Cytotoxic T lymphocytes (CTLs), activated dendritic cells, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). Independent testing data and the leave-one-out cross-validation method were used to evaluate model effectiveness and model performance, respectively. We identified five immunophenotypes (G1 to G5) based on the enrichment level for the four immune subsets. G2 had the worst prognosis and comprised highly enriched MDSCs and lowly enriched CTLs. G3 had the best prognosis and comprised lowly enriched MDSCs and Tregs and highly enriched CTLs. The average accuracy of T1-weighted contrasted MR radiomics models of the enrichment level for the four immune subsets reached 79% and predicted G2, G3, and the “immune-cold” phenotype (G1) according to our radiomics models. Our radiomic immunophenotyping models feasibly characterize the immunophenotypes of GBM and can predict patient prognosis.

Original languageEnglish
Article number3039
Pages (from-to)1-16
Number of pages16
Issue number10
Publication statusPublished - Oct 2020


  • First-order statistics
  • Glioblastoma
  • Gray-level co-occurrence matrix
  • Gray-level run length matrix
  • Immunophenotypes
  • Radiogenomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radiomic immunophenotyping of gsea-assessed immunophenotypes of glioblastoma and its implications for prognosis: A feasibility study'. Together they form a unique fingerprint.

Cite this